• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Can Integra LifeSciences Holdings (IART) Be Cheap On Its Pediatric Registry Milestone?

    Simply Wall St·10/02/2026 02:24:24
    Listen to the news

    Clinical milestone puts Integra LifeSciences in focus

    Integra LifeSciences Holdings (IART) has drawn fresh attention after announcing enrollment of the 100th patient in its AERA Pediatric Registry, a key step in gathering real world evidence for its Eustachian tube balloon dilation system.

    Recent price action has been mixed. Integra LifeSciences shares are up 33.97% on a year to date share price return, yet the 90 day share price return has declined 10.86% and the 3 year total shareholder return is down 57.37%. This points to improving momentum in the near term but a still weak longer term record.

    Scan beyond Integra LifeSciences Holdings and compare this pediatric-focused catalyst with other healthcare stocks on our hand picked 35 healthcare AI stocks that are pairing medical devices with AI driven capabilities.

    The recent rebound in Integra LifeSciences after a steep multi year slide puts a simple choice in front of you. Is this a reset level worth paying for now, or a watchlist name until the price improves?

    Most Popular Narrative: 40% Undervalued

    Integra LifeSciences Holdings last closed at $16.09, while the most followed narrative pegs fair value closer to $27. That gap reflects a view that operational clean up and cost work could matter more than the recent share price suggests.

    Analysts broadly agree that Integra's Compliance Master Plan and supply chain upgrades will stabilize operations and restore revenue. However, this may actually drive a structural step change in cost efficiency and supply reliability, leading to gross margin and earnings expansion well beyond conservative estimates as operational bottlenecks are permanently resolved across legacy and newly acquired sites.

    See why 2 investors see Integra LifeSciences Holdings as 40% undervalued.

    That storyline uses a 10.27% discount rate and assumes Integra LifeSciences reaches a fair value of $27, compared with the current $16.09 price. It rests on expectations for higher profit margins and steadier execution over time, which would support the view that today’s valuation underestimates future earnings power.

    On that basis, Integra LifeSciences would screen as materially undervalued, although the same narrative also flags regulatory risk, reliance on a concentrated product set, and pressure on pricing as key swing factors that could challenge those assumptions.

    Result: Fair Value of $27 (UNDERVALUED)

    Still, Integra LifeSciences faces real swing factors, including ongoing regulatory and quality remediation work, as well as heavy reliance on a relatively concentrated product portfolio.

    Find out about the key risks to this Integra LifeSciences Holdings narrative.

    Next Steps

    Mixed signals around Integra LifeSciences can feel confusing, yet this is exactly when fresh data matters most and speed helps you frame your own call. To weigh both the upside potential and the open questions, start by checking the 3 key rewards and 1 important warning sign.

    Looking for more Integra LifeSciences investment ideas?

    If Integra LifeSciences has your attention, treat this as a starting point and build a wider watchlist so you are not relying on a single outcome.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.